Quantum Leap Health Carecollaborative
Public records show a registered, tax-exempt organization in good standing.
Points to look into
- Raising each dollar of donations cost 64 cents.
These come from the organization's own tax return. There may be a good explanation; ask the charity.
What it says it does
THE MISSION OF QUANTUM LEAP HEALTHCARE COLLARBORATIVE IS TO PROVIDE MANAGEMENT AND FINANCIAL SUPPORT TO HEALTHCARE RESEARCH ORGANIZATIONS, PARTICULARLY INVOLVING BREAST CANCER RESEARCH AND TREATMENT.
- Income
- $45.5 million
- Spending
- $62.6 million
- Spent on programs
- 88%
- Reserves
- 2.1 months of spending
- Largest source of income
- fees for its services, 93%
- Employees
- 114
- Volunteers
- 15
- Highest pay
- $780,650, ceo
Source: Form 990 for the year ending December 31, 2024, filed with the Internal Revenue Service. Rating method 2026.2. How we rate
Financial health
Weak: 30 out of 100. Higher than 2% of charities in its peer group (human services, $10m to $100m).
Reserves
10 of 35Spendable reserves would cover 2.1 months of spending.
Debt
5 of 20It owes 72% of what it owns.
Living within its means
0 of 15Spending exceeded income by 37% of income.
Income trend
15 of 15Income rose 1% on the year before.
Spending floor
0 of 1588% of spending went to programs and raising each dollar of donations cost 64 cents.
Source: Form 990 for the year ending December 31, 2024, filed with the Internal Revenue Service. Rating method 2026.2. How we rate
Governance
Strong: 100 out of 100. Higher than 35% of charities in its peer group (human services, $10m to $100m).
Independent board
25 of 2511 of 12 voting board members are independent.
Conflict of interest policy
15 of 15Has a written conflict of interest policy.
Whistleblower policy
8 of 8Has a written whistleblower policy.
Record keeping policy
7 of 7Has a written policy on keeping and destroying records.
Board minutes
5 of 5Keeps minutes of board meetings.
Board sees the tax return
10 of 10Gave the board a copy of this return before filing it.
Pay set independently
5 of 5Sets its chief executive's pay through independent review and comparison.
Independent check of accounts
15 of 15Its accounts were audited by an independent accountant.
No reported misuse
10 of 10Reports no diversion of assets, excess benefits or loans to insiders.
Source: Form 990 for the year ending December 31, 2024, filed with the Internal Revenue Service. Rating method 2026.2. How we rate
Impact evidence
Describes programs. Its tax return describes what it does but we have found no measurable results in it.
Programs described in its return (4)
- $31.1 million spent. ISPY 2.2 - I-SPY 2.2 USES A 'SEQUENTIAL MULTIPLE ASSIGNMENT RANDOMIZED TRIAL' (SMART) DESIGN - THAT IS BOTH SMART AND ADAPTIVE. THE TRIAL CONSISTS OF UP TO THREE BLOCKS OF TREATMENT. THE FIRST, BLOCK A, INCLUDES NOVEL TARGETED THERAPIES, WITHOUT STANDARD CHEMOTHERAPY. IF A PATIENT ACHIEVES A COMPLETE RESPONSE AFTER BLOCK A, THEY CAN AVOID TOXIC CHEMOTHERAPY AND GO DIRECTLY TO SURGERY. IF THEY HAVE RESIDUAL CANCER, OR THE TREATMENT IS FOUND TO HAVE LITTLE EFFECT HALFWAY THROUGH THE COURSE OF TREATMENT, THEY ARE RECOMMENDED TO PROCEED TO TREATMENT IN BLOCK B. IN BLOCK B, PATIENTS ARE ASSIGNED A TREATMENT REGIMEN MOST LIKELY TO WORK FOR THEIR SUBTYPE, OFTEN COMBINED WITH CHEMOTHERAPY SINCE THE RISK OF TOXICITY IS MORE ACCEPTABLE IN PATIENTS WITH MORE RESISTANT CANCER. (CONTINUED ON SCHEDULE O)IF BLOCK B TREATMENT IS EFFECTIVE, THE PATIENT CAN SKIP ADDITIONAL CHEMOTHERAPY AND GO TO SURGERY. ONLY IF THEY STILL HAVE TUMOR LEFT AFTER BLOCK B, WILL THE PATIENTT GET RESCUE THERAPY WITH DOXORUBICIN AND CYCLOPHOSPHAMIDE A CHEMOTHERAPY REGIMEN THAT HAS BEEN AROUND FOR DECADES. AVERAGE OVERHEAD BOOKED TO PROGRAM IN FY2024 = 36.9%
- $2.3 million spent. DCIS - THE RE-EVALUATING CONDITIONS FOR ACTIVE SURVEILLANCE SUITABILITY AS TREATMENT: DUCTAL CARCINOMA IN SITU (RECAST DCIS) PLATFORM TRIAL IS A LANDMARK PHASE 2 TRIAL THAT IS CHANGING THE LENS THROUGH WHICH WE TREAT DCIS. THE STUDY IS AIMED AT PREVENTING THE PROGRESSION OF DCIS TO BREAST CANCER AND IS EVALUATING THREE INVESTIGATIONAL ENDOCRINE THERAPY ARMS.WITH THE OBJECTIVE TO AVOID OVER-TREATMENT OF LOW-RISK DCIS PATIENTS, THIS NEW TRIAL OFFERS DCIS PATIENTS ENDOCRINE THERAPY WITH THE INTENT TO IDENTIFY PATIENTS WHO ARE RESPONSIVE TO NON-INVASIVE TREATMENT AND HAVE THE OPTION TO OMIT SURGERY AND BE MONITORED VIA LONG-TERM ACTIVE SURVEILLANCE. (CONTINUED ON SCHEDULE O)A KEY ELEMENT IN REDUCING OVER TREATMENT OF DCIS IS IDENTIFYING BIOMARKERS THAT REFLECT THE RISK OF PROGRESSION SO THAT THOSE WITH LOW-RISK LESIONS ARE SPARED SURGERY. RECAST DCIS FEATURES THE ASSESSMENT OF MRI IMAGING AND MOLECULAR-BASED BIOMARKER ANALYSES IN ADDITION TO EVALUATING NEW INVESTIGATIONAL AGENTS IN THIS SETTING. IF PATIENTS AND THEIR PHYSICIANS AGREE, THEY MAY BE ABLE TO STAY ON ENDOCRINE THERAPY FOR UP TO THREE YEARS. AVERAGE OVERHEAD BOOKED TO PROGRAM IN FY2024 = 7.2%
- $271,185 spent. PHASE1B - PRE I-SPY IS AN OPEN-LABEL PHASE 1B PLATFORM STUDY DESIGNED TO EVALUATE SINGLE AGENTS OR COMBINATIONS IN A METASTATIC TREATMENT SETTING THAT MAY BE RELEVANT FOR BREAST CANCER PATIENTS WITH THE OVERALL GOAL OF MOVING PROMISING DRUG REGIMENS INTO THE I-SPY 2.2 TRIAL AND/OR OTHER ONCOLOGY-BASED TRIALS IN A TIMELY MANNER. THE PRIMARY OBJECTIVES OF THIS PLATFORM TRIAL ARE TO DETERMINE THE SAFETY AND TOLERABILITY OF NEW AGENTS/REGIMES IN PATIENTS WITH CERTAIN ADVANCED SOLID TUMORS AND BREAST CANCER WHILE OBTAINING PRELIMINARY EFFICACY DATA OF THE NEW AGENTS/REGIMES. THE STUDY WAS DEVELOPED TO HELP INVESTIGATORS AND INDUSTRY PARTNERS MEET THE SAFETY QUALIFICATIONS NECESSARY FOR PARTICIPATION IN I-SPY 2.2 (CONTINUED ON SCHEDULE O) TRIAL AND/OR OTHER PHASE II/III STUDIES. AVERAGE OVERHEAD BOOKED TO PROGRAM IN FY2024 = 7.00%
- $21.6 million spent. OTHER PROGRAMS INCLUDE BREAST CANCER TRIALS (BCT) MATCH, COVID-19 TRIALS, I-SPY 2.0, ENDOCRINCE OPTIMIZATION PROJECT (EOP) TRIALS, AND ONE SOURCE AI.
Source: Form 990 for the year ending December 31, 2024, filed with the Internal Revenue Service. Rating method 2026.2. How we rate
Legitimacy checks
Is it registered with the IRS? Passed.
Listed in the IRS master file of tax-exempt organizations as a 501(c)(3) charitable organization.
Source: Exempt Organizations Business Master File, Internal Revenue Service, file dated October 13, 2026.
Has the IRS revoked its tax-exempt status? Passed.
Not on the IRS automatic revocation list.
Source: Automatic revocation of exemption list, Internal Revenue Service, file dated October 13, 2026.
Are donations tax-deductible? Passed.
On the IRS list of organizations eligible to receive tax-deductible contributions.
Source: Publication 78 data: organizations eligible for tax-deductible contributions, Internal Revenue Service, file dated October 13, 2026.
Is it keeping up with its IRS filings? Passed.
Most recent return on file covers the year ending December 2024.
Source: Exempt Organizations Business Master File, Internal Revenue Service, file dated October 13, 2026.
How long has it been tax-exempt? Passed.
Recognized by the IRS since August 2006.
Source: Exempt Organizations Business Master File, Internal Revenue Service, file dated October 13, 2026.
Is it in good standing with state regulators? Passed.
Not on California's list of charities barred from soliciting. Other states are not yet checked.
Source: May Not Operate or Solicit for Charitable Purposes list, California Attorney General, Registry of Charities and Fundraisers, file dated October 21, 2026.
Ratings and checks are our reading of public records, using the published method. They are not a statement about anyone's honesty. If you work for this organization, you can send corrections or results, confirm you want gifts through Veridonate, or ask to be removed from giving.